Subscribe
blue-pills-drugs
Urusaurus / shutterstock.com
16 January 2017Big Pharma

English High Court refers Truvada SPC case to CJEU

The English High Court has referred a supplementary protection certificate (SPC) dispute over Truvada (emtricitabine/tenofovir) to Europe’s highest court, the Court of Justice of the European Union (CJEU).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
French court knocks out Gilead Truvada SPC
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025

More on this story

Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
French court knocks out Gilead Truvada SPC
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.

More on this story

Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
French court knocks out Gilead Truvada SPC
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress